Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2

NCT03005184 is registered in ClinicalTrials.gov with Vanderbilt University Medical Center as lead sponsor.

NCT NCT03005184
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03005184 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2
Lead sponsor
Vanderbilt University Medical Center
Phase
Phase 2
Overall status
Withdrawn
Start date
September 30, 2017
Completion date
January 31, 2020
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure nyha class i, heart failure nyha class ii, heart failure nyha class iii